Harmony Biosciences
HRMY
84 hedge funds and large institutions have $790M invested in Harmony Biosciences in 2021 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 32 increasing their positions, 9 reducing their positions, and 6 closing their positions.
450% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 6
256% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 9
47% more funds holding
Funds holding: 57 → 84 (+27)
0.92% more ownership
Funds ownership: 48.28% → 49.2% (+0.92%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
13% less capital invested
Capital invested by funds: $907M → $790M (-$117M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$30.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.5M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$8.31M |
| 4 |
State Street
Boston,
Massachusetts
|
+$6.46M |
| 5 |
PA
Perceptive Advisors
New York
|
+$5.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$69.3M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$57.4M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$3.3M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$666K |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$566K |
HRMY Hedge Fund Activity: Q2 2021 in Review
84 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q2 2021, worth a combined $790M — down 13% from $907M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new HRMY positions and 6 closed out — a net gain of 27 holders — while 32 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $30.2M. The largest seller was Fidelity Investments, cutting an estimated $69.3M.
- 84 institutional investors held Harmony Biosciences (HRMY) as of Q2 2021, up from 57 in Q1 2021.
- Funds reported $790M of Harmony Biosciences stock for Q2 2021, down 13% quarter-over-quarter.
- 33 funds opened new Harmony Biosciences positions in Q2 2021 and 6 closed out, a net change of +27 holders.
- The largest Harmony Biosciences buyer in Q2 2021 was BlackRock, an estimated $30.2M added.
- The largest Harmony Biosciences seller in Q2 2021 was Fidelity Investments, an estimated $69.3M sold.
Based on aggregated 13F filings for Q2 2021.